Summit Therapeutics PLC Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed on July 14, 2020, by Summit Therapeutics PLC, a foreign private issuer. The report covers corporate governance actions taken on July 13, 2020, specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a director appointment and equity grant.
Material Changes
- Board Appointment: Ujwala Mahatme was elected as a non-executive director on July 13, 2020.
- Equity Grant: Ms. Mahatme was granted options to purchase 213,340 American Depositary Shares (ADSs).
- Grant Terms: The exercise price is $3.16 per ADS, reflecting the closing price on the grant date.
- Vesting Schedule: 200,000 options vest in four equal annual installments of 50,000 starting one year from the grant date. The remaining 13,340 options vest in full on December 31, 2020.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard equity compensation disclosure.
Investor Verification Points
- Confirm the total number of outstanding options granted to Ms. Mahatme (213,340 ADSs).
- Verify the exercise price of $3.16 per ADS against market data for July 13, 2020.
- Review the specific vesting conditions for the 13,340 options scheduled to vest on December 31, 2020.
- Check subsequent filings for any changes to the Board composition or equity plan limits.